A new federal drug marketplace launched by the Trump administration is now selling an oral version of Novo Nordisk’s weight-loss drug Wegovy for about $149 a month, a fraction of what the injectable version has cost patients paying cash. The site, TrumpRx.gov, lists the tablet at $149 for a 30-day supply against an original price above $1,300, a discount the administration credits to pricing deals it struck with drugmakers over the past year. The number is real and live today — but who can use it, and how long the lowest rate holds, depends on details well past the headline price.
The $149 Price, Straight From the Government’s Own Site
TrumpRx.gov, the online marketplace the administration built to advertise negotiated drug prices, lists the Wegovy tablet in 1.5-milligram and 4-milligram strengths at $149 for a 30-count monthly supply. The site puts the original price for that supply at $1,349.02 — in line with the roughly $1,300-a-month list price the injectable form of Wegovy has publicly carried for years — so the advertised discount runs 78% to 89% off list, depending on strength. The price applies to self-pay customers who present a coupon at a participating pharmacy rather than billing an insurer.
The $149 rate carries a catch tied to today’s date. TrumpRx’s own terms describe the price as a limited-time offer for the 4-milligram tablet good only through August 31, 2026; starting the next day, that dose reverts to $199 a month. The 1.5-milligram starting dose is listed at $149 without the same expiration language, meaning the lowest entry price should persist, but the higher-strength pill many patients eventually need is about to get more expensive.
To use the coupon, a buyer must be 18 or older, a U.S. or territory resident, and hold a valid prescription for the brand. The offer is restricted to self-pay use: TrumpRx’s terms require anyone with Medicare, Medicaid, TRICARE, Department of Defense or other government health coverage to forgo billing that coverage for the purchase and to avoid counting the cost toward an insurance deductible or out-of-pocket maximum.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
A Bigger Deal Behind the Sticker Price
The discount traces back to a most-favored-nation pricing agreement the administration announced with Novo Nordisk and Eli Lilly, aiming to bring U.S. prices for the GLP-1 class of drugs closer to what other wealthy countries pay. The companies agreed to sell versions of their obesity and diabetes medications through TrumpRx at steep discounts to the sticker prices that made headlines for years, in exchange for regulatory and trade considerations from the administration.
When the deal was first unveiled in the original November 2025 announcement, the $149-a-month price was described as a future target for an oral obesity pill still pending federal approval. Ten months later, that promise has become an actual listing on a government website, with a real price, a real expiration date attached to part of it, and real purchase terms — a rare case of a drug-pricing pledge showing up as a working product page rather than a talking point.
Injectable versions of the same drug family, including Wegovy’s original injection form and Eli Lilly’s Zepbound and Mounjaro, remain listed on TrumpRx at prices well above the oral pill’s $149, even after the negotiated cuts, because the injectable formulations still carry higher manufacturing and packaging costs than a tablet. The pill’s price is the sharpest cut in the deal so far, which is part of why the administration is promoting it.
The Insurance Catch Older Adults Should Weigh
The self-pay requirement matters most for people already covered by Medicare Part D or a Medicare Advantage drug plan. Someone who buys the pill through TrumpRx and pays $149 in cash cannot also submit that purchase to their Part D plan or count it toward their plan’s deductible or true out-of-pocket maximum — the two systems do not combine. A person who already has drug coverage needs to compare the actual copay their plan would charge against the $149 cash price before defaulting to the coupon.
That comparison matters because TrumpRx measures its 78% to 89% savings against the full retail list price, not against what an insured patient typically already pays after a copay or coinsurance. A Medicare enrollee whose Part D plan already covers a GLP-1 medication at a $25 or $50 copay may still come out ahead using their existing coverage rather than switching to the cash lane, even with the headline discount attached to the TrumpRx price.
What is not yet clear is whether $149 becomes the durable price for the oral pill or another limited-time entry rate that resets once the introductory period ends, the way the 4-milligram tablet’s price is scheduled to do the day after this article publishes. TrumpRx has expanded its drug list several times since launch, and each expansion has arrived with its own fine print on eligibility and duration — a pattern that leaves patients checking the site before every refill rather than assuming last month’s price still holds.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
